866-997-4948(US-Canada Toll Free)

Geodon Analysis and Forecasts from 2002 to 2017

Published By :

GlobalData

Published Date : Jul 2011

Category :

Therapeutic Area

No. of Pages : 29 Pages


GlobalDatas pharmaceuticals report, Geodon Analysis and Forecasts from 2002 to 2017 provides Geodon sales estimates for US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2017). The report also includes information on Schizophrenia market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts. 

Scope
  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Geodon including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Geodon including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2011-2017 for Geodon in each of the seven major markets
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of content

1 Table of contents
1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Introduction 4
2.1 Schizophrenia 4
2.2 Symptoms 4
2.3 Schizophrenia Market 4
2.4 Epidemiology 4
2.5 Etiology 5
2.5.1 Genetic Factors 5
2.5.2 Environmental Factors 5
2.5.3 Abnormal Brain Structure 6
2.6 GlobalData Report Guidance 6

3 Schizophrenia: Market Characterization 7
3.1 Schizophrenia Market 7
3.2 Schizophrenia Market Forecasts and CAGR 7
3.3 Drivers of Schizophrenia Therapeutics Market 8
3.3.1 Patent Expiry of Leading Marketed Drugs 8
3.3.2 Increasing Patient Pool 8
3.3.3 High Prescription Rates 8
3.3.4 Low Patient Compliance Rate 8
3.3.5 High Unmet Need 8

4 Classification of Schizophrenia 9
4.1 Age of Onset of Schizophrenia 9
4.1.1 Pediatric / Adolescent / Childhood Schizophrenia 9
4.1.2 Adult Schizophrenia 10
4.2 Associated Symptoms 10
4.2.1 Paranoid Schizophrenia 10
4.2.2 Disorganized Schizophrenia 10
4.2.3 Catatonic Schizophrenia 10
4.2.4 Residual Schizophrenia 10
4.2.5 Undifferentiated Disorder 10

5 Treatment for Schizophrenia 11
5.1 Crisis Resolution Teams (CRT) 11
5.2 Voluntary and Compulsory Detention 11
5.3 Antipsychotics 11
5.3.1 Typical Antipsychotics 11
5.3.2 Atypical Antipsychotics 12
5.3.3 Increased Mortality in Elderly Patients with Dementia-Related Psychosis 12

6 Geodon/ Zeldox 13
6.1 Introduction 13
6.2 Mechanism of Action 13
6.3 Clinical Studies 13
6.4 Approval History 14
6.5 Factors Affecting Sales of Geodon 14
6.5.1 Generic Erosion 14
6.5.2 Weight Gain 14
6.5.3 Lowest Efficacy 14
6.5.4 High Competition 14
6.6 Drug Risk Benefit Score 15
6.6.1 Efficacy 15
6.6.2 Safety 15
6.6.3 Compliance 16
6.6.4 Dosing Convenience 16
6.7 Intensity of Competition 16
6.8 Sales Forecasts 16
6.8.1 Target Patient Pool of Geodon 16
6.8.2 Dosing 17
6.8.3 Market Penetration 17
6.8.4 Annual Cost of Therapy 17
6.8.5 Sales Projections of Geodon 18

7 Schizophrenia Market: Appendix 26
7.1 Market Definitions 26
7.2 Abbreviations 26
7.3 Research Methodology 26
7.4 Drug Sales Estimates Model 28
7.5 Contact Us 28
7.6 Disclaimer 29
7.7 Sources 29

List of Table


Table 1: CATIE, Phase III Clinical Trials Results, Geodon 13
Table 2: Approval History of Geodon 14
Table 3: Drug Risk Benefit Score of Geodon 15
Table 4: Safety of Geodon 15
Table 5: Annual Cost of Therapy ($), 2010 17
Table 6: Geodon, Schizophrenia, Global, Estimated Sales ($m), 20022017 18
Table 7: Geodon, Schizophrenia, The US, Estimated Sales ($m), 20022017 19
Table 8: Geodon, Schizophrenia, The UK, Estimated Sales ($m), 20022017 20
Table 9: Geodon, Schizophrenia, France, Estimated Sales ($m), 20022017 21
Table 10: Geodon, Schizophrenia, Germany, Estimated Sales ($m), 20022017 22
Table 11: Geodon, Schizophrenia, Italy, Estimated Sales ($m), 20022017 23
Table 12: Geodon, Schizophrenia, Spain, Estimated Sales ($m), 20022017 24

List of Chart


Figure 1: Risk of Developing Schizophrenia 5
Figure 2: Environmental Factors in the Development of Schizophrenia 6
Figure 3: Schizophrenia, Global, Market Size Forecasts ($bn), 20102020 7
Figure 4: Classification of Schizophrenia based on the Age of Disease Onset 9
Figure 5: Target Patient Pool of Geodon 16
Figure 6: Geodon, Schizophrenia, Global, Estimated Sales ($m), 20022017 18
Figure 7: Geodon, Schizophrenia, The US, Estimated Sales ($m), 20022017 19
Figure 8: Geodon, Schizophrenia, The UK, Estimated Sales ($m), 20022017 20
Figure 9: Geodon, Schizophrenia, France, Estimated Sales ($m), 20022017 21
Figure 10: Geodon, Schizophrenia, Germany, Estimated Sales ($m), 20022017 22
Figure 11: Geodon, Schizophrenia, Italy, Estimated Sales ($m), 20022017 23
Figure 12: Geodon, Schizophrenia, Spain, Estimated Sales ($m), 20022017 24
Figure 13: Geodon, Schizophrenia, Global, Sales Distribution in Major Countries (%), 2011 25

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *